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Summary
 
The interleukin (IL)-12 receptor (R)
 
b
 
2 subunit is the critical molecule involved in maintaining
IL-12 responsiveness and controlling T helper cell type 1 lineage commitment. We demon-
strate that IL-12 and interferon (IFN)-
 
g
 
 play separate, but complementary, roles in regulating
IL-12R
 
b
 
2 expression on antigen-specific CD4
 
1
 
 T cells. These results are consistent with our
previous observation that IL-12 can promote autoimmune disease through IFN-
 
g
 
–indepen-
dent as well as –dependent pathways. Therefore, we compared the induction of IL-12 by, and
the expression of the IL-12R
 
b
 
2 subunit on, myelin basic protein (MBP)-specific T cells from
experimental allergic encephalomyelitis (EAE)-susceptible SJL (H-2
 
s
 
) mice and from EAE-
resistant B10.S mice (H-2
 
s
 
). B10.S mice had an antigen-specific defect in their capacity to upreg-
ulate the IL-12R
 
b
 
2 subunit. Defective expression was not secondary to the production of sup-
pressive cytokines, but to a failure of B10.S MBP-specific T cells to upregulate CD40 ligand
expression and to induce the production of IL-12. IL-12R
 
b
 
2 expression as well as encephalito-
genicity of these cells could be restored by the addition of IL-12. These results suggest that the
development of immunotherapies that target the IL-12R
 
b
 
2 subunit may be useful for the
treatment of autoimmune diseases.
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A
 
nimal models of organ-specific autoimmune diseases
are uniformly mediated by autoreactive Th1 lympho-
cytes, whether they develop spontaneously or are induced
by immunization with autoantigen in CFA. For example,
the production of IFN-
 
g
 
 and/or TNF-
 
a
 
 has been impli-
cated in the pathogenesis of experimental allergic encepha-
lomyelitis (EAE),
 
1
 
 myasthenia gravis, collagen-induced ar-
thritis (CIA), insulin-dependent diabetes mellitus (IDDM)
in nonobese diabetic mice, and the spectrum of organ-
specific autoimmune disease that follows neonatal thymec-
tomy (1–8). Th1 cells have also been implicated in the
pathogenesis of organ-specific diseases in humans, includ-
ing multiple sclerosis, IDDM, inflammatory arthritis, and
autoimmune thyroiditis (9–12). Although successful induc-
tion of autoimmune diseases in mice genetically deficient
in IFN-
 
g
 
, TNF-
 
a
 
, or lymphotoxin 
 
a
 
 have cast doubt on
the involvement of a single proinflammatory Th1 cytokine
in disease pathogenesis (13–16), and have even demon-
strated protective effects of some of these proinflammatory
mediators, studies in a number of disease models demon-
strate a critical role for IL-12 in the generation of Th1 ef-
fectors (17). IFN-
 
g
 
2/2
 
 mice exhibit enhanced susceptibility
to EAE as well as to CIA, whereas IL-12
 
2/2
 
 mice are
completely resistant to induction of either disease (18–20).
Furthermore, neutralization of IL-12 in IFN-
 
g
 
2/2
 
 mice
protected them from both EAE and CIA. In SJL mice,
administration of a polyclonal antiserum to IL-12 was pro-
tective during either the induction or effector phase of
adoptively transferred EAE (20, 21). Similarly, neutraliza-
tion of IL-12 in mice with established colitis induced by
2,4,6-trinitrobenzene sulfonic acid (TNBS) led to rapid
and complete recovery (22); furthermore, anti–IL-12, but
not anti–IFN-
 
g
 
, was recently found to be therapeutic in
another model of autoimmune colitis that arises in IL-10
 
2/2
 
mice (23). Interference with the biological activity of IL-12
may therefore be an appropriate target for the treatment of
autoimmune disease in humans.
Collectively, these studies suggest that the successful dif-
ferentiation and/or function of autoimmune effector cells
must be dependent on their ability to respond to quantities
of IL-12 that are available in the microenvironment during
critical time points. Studies from several groups have dem-
 
1
 
Abbreviations used in this paper:
 
 CD40L, CD40 ligand; CIA, collagen-
induced arthritis; EAE, experimental allergic encephalomyelitis; MBP,
myelin basic protein; NP, nucleoprotein; PLP, proteolipid protein. 
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onstrated that the expression of the IL-12 receptor plays a
critical role in determining the Th1/Th2 balance during the
course of an immune response. The IL-12R
 
b
 
2 subunit is
not expressed on resting T cells, but is induced at low levels
after engagement of the TCR by antigen. Maintenance of a
level of IL-12R
 
b
 
2 subunit expression sufficient to allow
signaling by IL-12 and therefore Th1 differentiation is criti-
cally dependent on the relative amounts of IFN-
 
g
 
 and IL-4
in the microenvironment during T cell priming (24–26).
IL-4 inhibits IL-12R
 
b
 
2 subunit expression, but this inhibi-
tion can be overcome by IFN-
 
g
 
, even in cells that have be-
gun to differentiate along the Th2 pathway. Although the
IL-12R
 
b
 
2 subunit can be induced in the presence of exoge-
nous IL-12 in the absence of IFN-
 
g
 
 and IL-4, the role of
endogenous IL-12 itself in direct induction of IL-12R
 
b
 
2
expression has not yet been examined. The direct induction
of IL-12R
 
b
 
2 expression may be particularly relevant to the
development of autoimmune effectors in IFN-
 
g
 
2/2
 
 mice.
In this report, we initially used cytokine-deficient mice
and neutralizing anti-cytokine mAbs to critically examine
the relative roles of IL-12 and IFN-
 
g
 
 in the induction and
maintenance of the IL-12R
 
b
 
2 subunit on CD4
 
1
 
 T cells
that have been primed against a conventional foreign anti-
gen. We demonstrate that in wild-type mice IL-12 and
IFN-
 
g
 
 play separate as well as complementary roles in reg-
ulating IL-12R
 
b
 
2 expression. However, sustained expres-
sion of IL-12R
 
b
 
2 can be induced in IFN-
 
g
 
2/2
 
 mice by an
IL-12–dependent pathway. These findings raised the possi-
bility that the regulation of IL-12R
 
b
 
2 expression by IL-12
itself may play a role in the generation of pathogenic au-
toreactive T cells. Therefore, we extended these studies
and compared the induction of the IL-12R
 
b
 
2 subunit on
MBP-specific T cells derived from a strain of mice (SJL,
H-2
 
s
 
) that is highly susceptible to EAE with T cells from a
strain (B10.S, H-2
 
s
 
) that is resistant to EAE. We demon-
strate that B10.S mice have an antigen-specific defect in
their capacity to upregulate the IL-12R
 
b
 
2 subunit. This
defective expression of the IL-12R
 
b
 
2 subunit is not sec-
ondary to the production of suppressive cytokines or to a
decreased functional avidity of the TCR, but to a failure of
the B10.S MBP-specific T cells to upregulate CD40 ligand
(CD40L) expression, which is an important stimulus for
the endogenous production of IL-12 by APCs. Because
IL-12R
 
b
 
2 expression as well as the encephalitogenicity of
these cells can be restored by the addition of exogenous
IL-12 or IL-12–inducing agents (27, 28), we classify the
B10.S MBP-specific cells as a novel population of auto-
reactive preautoimmune T (T
 
pre-A
 
) cells that have emerged
from the thymus with a defect in their capacity to dif-
ferentiate into mature Th1 effector cells. However, these
autoreactive cells retain the potential to differentiate into
pathogenic T cells upon exposure to IL-12 induced by en-
vironmental or infectious agents.
 
Materials and Methods
 
Mice.
 
SJL/J and C57BL/6 mice were obtained from the Na-
tional Cancer Institute. Breeding pairs of C57BL/6 IL-12
 
2/2
 
(N6) and C57BL/6 IFN-
 
g
 
2/2
 
 were originally provided by J. Ma-
gram (Hoffman-La Roche, Nutley, NJ) and D. Dalton and T.
Stewart (Genetech Inc., South San Francisco, CA), respectively.
B10.S mice were obtained from both McLaughlin Research In-
stitute and Taconic Farms. All mice were housed under specific
pathogen-free conditions. They were exclusively female and be-
tween 2 and 4 mo of age when experiments were started.
 
Peptides.
 
Peptides corresponding to residues 260–283 of In-
fluenza A nucleoprotein (NP
 
260–283
 
, ARSALILRGSVAHKSCL-
PACVYGP), residues 87–106 of myelin basic protein (MBP
 
87–106
 
,
VVHFFKNIVTPRTPPPSQGK), and residues 139–151 of pro-
teolipid protein (PLP
 
139–151
 
, HSLGKWLGHPDKF) were synthe-
sized and purified by HPLC by the Laboratory of Molecular
Structure, Peptide Synthesis Laboratory (NIAID, National Insti-
tutes of Health [NIH]). Chicken OVA was purchased from
Sigma Chemical Co.
 
Immunization.
 
Mice were immunized subcutaneously at four
sites over the flanks with an emulsion consisting of equal volumes
of CFA (DIFCO Labs.) and antigen dissolved in PBS. Doses of
antigen used were as follows: MBP
 
87–106
 
,
 
 
 
100 
 
m
 
g; NP
 
260–283
 
, 5 
 
m
 
g;
OVA, 100 
 
m
 
g; PLP
 
139–151
 
, 100 
 
m
 
g.
 
Disease Induction.
 
For disease induction by adoptive transfer,
donor mice were immunized with 100 
 
m
 
g of MBP or PLP in
CFA (1:1); 10–14 d later, draining LN cells were cultured for 96 h
with MBP or PLP. Recovered cells (6 
 
3 
 
10
 
7
 
) were injected in-
traperitoneally into naive syngeneic recipients that were exam-
ined daily for signs of EAE and rated on a five-point scale as pre-
viously described (20).
 
Cell Cultures.
 
10–14 d after immunization, draining LN cells
(axillary and inguinal) were removed and processed as previously
described (20). In brief, single cell suspensions of spleen or LN tissue
were prepared by passage through wire mesh and red blood cells
lysed with ACK buffer (NIH Media Unit). Cells (4 
 
3
 
 10
 
6
 
/ml) were
cultured in RPMI 1640 containing 10% FCS and standard supple-
ments (25) for 24–72 h in the presence of MBP
 
87–106
 
 (50 
 
m
 
g/ml),
NP
 
260–283
 
 (5 
 
m
 
g/ml), PLP (50 
 
m
 
g/ml), or OVA (100 
 
m
 
g/ml). To
generate short-term lines, draining LN cells were cultured in MBP
or NP for 4 d, washed extensively, and rested for 7 d in complete
media. For maintenance of lines, T cells (10
 
6
 
/ml) were restimu-
lated with antigen in the presence of irradiated, syngeneic spleno-
cytes (4 
 
3
 
 10
 
6
 
/ml) every 10 d. For IL-12 assays, T cells (10
 
6
 
/ml)
were restimulated with or without antigen in the presence of syn-
geneic peritoneal exudate macrophages (5 
 
3
 
 10
 
5
 
/ml). To generate
peritoneal exudate macrophages, B10.S or SJL mice were injected
with 3 ml fluid thioglycollate media (NIH Media Unit). 3 d later,
macrophages were removed from the peritoneum of treated mice,
washed, and used in experiments. In some experiments, cells were
purified using T cell enrichment columns (R&D Systems). T and/or
NK cell depletion was performed by treating cells with anti-
Thy1.2 (clone HO-13.4) culture supernatants or anti-NK1.1 anti-
body (clone PK136) followed by treatment for 45 min at 37
 
8
 
C
with rabbit complement (Cedarlane Labs.).
 
Proliferation Assays.
 
LN cells (5 
 
3 
 
10
 
5
 
/0.2 ml) were cultured
with various concentrations of antigen or with media alone for
4 d in 96-well round-bottomed plates (Costar Corp.). Wells were
pulsed for the final 16 h of culture with 1 
 
m
 
Ci of [
 
3
 
H]TdR (Am-
ersham) and counted as previously described (20).
 
Antibodies and Cytokines.
 
Where specified, cytokines or neu-
tralizing antibodies were added to the primary cultures as follows:
IL-12, 20 ng/ml (gift of S. Wolf, Genetics Institute, Cambridge,
MA); recombinant murine IFN-
 
g
 
, 30 ng/ml (PharMingen); recom-
binant murine IL-10, 10 ng/ml (PharMingen); anti–mouse IFN-
 
g
 
,
10 
 
m
 
g/ml (clone XMG 1.2); rat anti–mouse IL-12, 10 
 
m
 
g/ml 
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(clone C17.8); rat anti–mouse IL-10, 10 
 
m
 
g/ml (clones SXC-1
and SXC-2); rat IgG, 10 
 
m
 
g/ml (Sigma Chemical Co.); and anti-
CD3 (2C11), 1.0 
 
m
 
g/ml. In certain studies, mice were injected
intraperitoneally on days 0, 3, and 6 with 1 mg of either control
rat IgG or rat anti–mouse IL-10 (clones SXC-1 and SXC-2).
 
Northern Blot Analysis.
 
Total RNA was isolated from LN cell
cultures using RNAzol RNA isolation solvent (Tel-Test). Sam-
ples (10 
 
m
 
g of total RNA per lane) were run on a 1.2% agarose
gel containing MOPS buffer and formaldehyde, and blotted onto
a Hybond-N nylon membrane (Amersham). Membranes were
baked for 2 h at 80
 
8
 
C, then probed for murine IL-12R
 
b
 
2
subunit, murine IL-12R
 
b
 
1 subunit, or 
 
b
 
-actin. The following
primer sets (Bio-Synthesis) were used to generate oligonucleotide
cDNA probes: IL-12R
 
b
 
2 forward CTG CAC CCA CTC ACA
TTA AC; IL-12R
 
b
 
2 reverse CAG TTG GCT TTG CCC TGT
GG; IL-12R
 
b
 
1 forward GAG GAG GCG GCT CTC CTC
AG; IL-12R
 
b
 
1 reverse ACA TTC CTC CTG CTC CAG GG.
The 
 
b
 
-actin primer set was purchased from Clontech. PCR was
performed for 40 cycles with the following parameters: 94
 
8
 
C, 30 s;
58
 
8
 
C, 30 s; 72
 
8
 
C, 1 min. cDNA probes were run on a 1.2% aga-
rose gel, and purified using the Wizard PCR DNA purification
system (Promega). PCR fragments (50 ng) were labeled with
[32P]dCTP using an oligolabeling kit (Pharmacia). Blots were
prehybridized for 1 h at 428C, followed by overnight hybridiza-
tion with labeled probe at 428C. Blots were then washed for 30
min in 23 SSC, 0.1% SDS buffer (room temperature) followed
by 30 min in 0.13 SSC, 0.1% SDS buffer (558C for IL-12Rb2
and IL-12Rb1; 658C for b-actin).
PCR. cDNA was reverse transcribed from 5 mg of RNA us-
ing Superscript II (GIBCO BRL). The following CD40L primers
have been previously described: forward CCC TTA AGC TTG
CAT GAT AGA AAC ATA corresponding to residues 10–26;
and reverse TAG AGC TCG AGG TTC AGA GTT TGA GTA
AGC C corresponding to residues 778–786 (29). A competitive
PCR MIMIC was constructed from a kit according to the manu-
facturer’s instructions (Clontech). The pMus-3 plasmid (gift of
Dr. Nancy Noben-Trauth, NIH) was used in conjunction with
the following primers to quantitate b2 microglobulin: forward
TGA CCG GCT TGT ATG CTA TC; reverse CAG TGT
GAG CCA GGA TAT AG. PCR reactions were carried out us-
ing Ready To Go PCR beads (Pharmacia) with 1 ml of MIMIC
and 2 ml of cDNA reaction. PCR was performed for 40 cycles
with the following parameters: 948C, 30 s; 588C, 30 s; 728C, 1 min.
PCR products were separated on a 1.2% agarose gel, and densi-
tometry performed on an Eagle Eye Gel Reader (Stratagene). A
relative ratio of CD40L/b2 microglobulin was calculated, and
data were expressed as the percentage change of stimulated levels
of CD40L/b2 microglobulin compared with background levels.
Cytokine ELISA. IFN-g was quantified using a sandwich
ELISA technique based on noncompeting pairs of antibodies as
previously described (28). IL-12p40 was quantified using the
mAbs produced by clones C17.5 and C15.6 (gifts of G. Trin-
chieri, Wistar Institute, Philadelphia, PA) for capture and detec-
tion, respectively.
Results
Independent Effects of IL-12 and IFN-g on the Expression of
the IL-12R. Previous studies have focused either on the
role of IFN-g in the upregulation or the role of IL-4 in the
downregulation of IL-12Rb2 expression (25, 30). However,
as IL-12 is a potent inducer of IFN-g production by T and
NK cells, it was impossible to determine from these experi-
ments whether IL-12 directly, or indirectly via IFN-g, in-
duced the expression of IL-12R. To distinguish between these
possibilities, we immunized C57BL/6 wild-type, IL-122/2,
and IFN-g2/2 mice with OVA in CFA. 10 d later, draining
LN cells were cultured in vitro for 3 d. Total RNA was ex-
tracted and used to perform Northern blot analysis. LN cells
from C57BL/6 wild-type mice upregulated IL-12Rb2 sub-
unit mRNA strongly in response to stimulation with OVA
in vitro (Fig. 1 A); the level of IL-12Rb2 mRNA was
diminished by the addition of anti–IL-12 or anti–IFN-g
to the cultures. OVA-reactive LN cells from IFN-g2/2
mice also upregulated IL-12Rb2 subunit mRNA to a level
comparable with that induced on wild-type LN cells (Fig.
1 B). The addition of anti-IL-12 to cultures of OVA-
primed LN cells from IFN-g2/2 mice markedly reduced
their expression of IL-12Rb2; conversely, the addition of
IL-12 to these cultures markedly enhanced the level of ex-
pression of IL-12Rb2 subunit above that seen when the
cells were stimulated with OVA alone. In contrast to the
results with cells from IFN-g2/2 mice, only weak upregu-
lation of IL-12Rb2 subunit expression in response to stim-
ulation with OVA was seen with LN cells from IL-122/2
mice; IL-12Rb2 expression was moderately enhanced by
the addition of exogenous IFN-g to the cultures (Fig. 1 C).
Taken together, these studies demonstrate that a low level
of IL-12Rb2 expression is induced by TCR signaling alone
and that IL-12 and IFN-g have independent as well as com-
plementary effects in promoting/maintaining the expres-
sion of the IL-12Rb2 subunit.
B10.S MBP-reactive T Cells Fail to Induce IL-12p40 Pro-
duction by Peritoneal Exudate Macrophages and Manifest a Defi-
ciency in CD40L Expression. We have previously shown
that B10.S, but not SJL mice, are resistant to the induction
of EAE and that the major difference between these strains
was that T cells from B10.S, but not SJL mice, demon-
strated an antigen-specific defect in IFN-g production
upon activation in vitro (28). Since our data clearly dem-
onstrated that endogenous IL-12 is required for optimal
IL-12Rb2 subunit expression, we questioned if the defect
in the ability of B10.S MBP-reactive T cells to produce
IFN-g was secondary to a failure of APCs to produce IL-12.
It is unlikely that an intrinsic defect in IL-12 production is
present in B10.S APCs, as it would be manifested as im-
paired IFN-g production in response to multiple antigens,
whereas our results indicate marked antigen-specificity.
Furthermore, purified dendritic cells and splenocytes from
B10.S and SJL mice produced comparable amounts of
IL-12p70 heterodimer when stimulated with either anti-
CD40 or LPS/IFN-g (data not shown). Therefore, it
seemed more likely that any deficiency in IL-12 produc-
tion must result from a defect of the T cell to prime the
APCs to produce IL-12. We generated B10.S MBP- and
NP-reactive T cell lines and stimulated them with antigen
in the presence of syngeneic peritoneal exudate macro-
phages. After 48 h of stimulation, B10.S NP-reactive T cell
lines induced high levels of IL-12p40 production by mac-
rophages, whereas B10.S MBP-reactive T cell lines failed972 IL-12 Receptor b2 Subunit and Autoimmunity
to induce any detectable IL-12p40 production (Fig. 2 A).
In contrast, SJL MBP- and NP-reactive T cell lines in-
duced comparable amounts of IL-12p40 production from
macrophages (Fig. 2 B).
Because the interaction of CD40L on T cells and CD40
on APCs is a major stimulus for IL-12 production, these
results raised the possibility that the failure of activated
B10.S MBP-reactive T cells to express sufficient levels of
CD40L upon activation is responsible for their failure to
prime APCs to produce IL-12. We used a competitive
PCR mimic to quantitate the relative levels of CD40L
mRNA expressed upon antigenic activation by B10.S
MBP- and NP-reactive LN cells. MBP-reactive LN cells
failed to upregulate CD40L mRNA, whereas NP-reactive
LN cells upregulated CD40L mRNA eightfold over un-
stimulated background levels (Fig. 3). Thus, the relative
deficiency in CD40L expression by B10.S MBP-reactive
LN cells may account for their failure to induce IL-12 pro-
duction by APCs.
MBP-specific T Cells from EAE-resistant B10.S Mice Fail to
Upregulate IL-12Rb2 Subunit mRNA. To test directly
whether the failure of the B10.S MBP-specific T cells to
induce IL-12 leads to a deficiency in the expression of ade-
quate levels of IL-12Rb2 subunit, draining LN cells from
SJL and B10.S mice that had been primed 12 d previously
with a combination of MBP and NP in CFA were cultured
in vitro for 72 h with either MBP or NP and evaluated for
IL-12R expression. LN cells from SJL mice upregulated
IL-12Rb2 subunit mRNA strongly in response to stimula-
tion with either MBP or NP (Fig. 4 A, left). In contrast,
LN cells from B10.S mice upregulated IL-12Rb2 subunit
mRNA only in response to stimulation with NP, but not
MBP (Fig. 4 A, right). Since NK cells and dendritic cells
have been reported to express IL-12R (26, 31), T cells
were purified from LN cells from immunized B10.S mice
and depleted of NK cells. These T cells were combined
with T cell–depleted, NK cell–depleted splenocytes from
naive B10.S mice and stimulated for 72 h, then evaluated
for IL-12Rb2 subunit expression. Results similar to those
shown in Fig. 4 A were obtained, thus excluding dendritic
cells or NK cells as the source of IL-12R observed (Fig.
4 B). In contrast to the IL-12Rb2 subunit, which was in-
duced only upon antigen stimulation, IL-12Rb1 subunit
was constitutively expressed with no consistent patterns of
antigen-induced upregulation (Fig. 4 A), in agreement
with previously published reports (25, 26).
IL-12Rb2 Subunit mRNA Expression Correlates with Sus-
ceptibility to EAE. We have previously demonstrated that
the addition of pharmacological concentrations of IL-12 to
cultures of B10.S MBP-reactive LN cells restored their
ability to produce IFN-g and converted them into enceph-
alitogenic effectors (28). Indeed, the addition of exogenous
IL-12 restored the ability of the B10.S MBP-reactive LN
cells to upregulate the expression of IL-12Rb2 subunit
mRNA in an antigen-specific, dose-dependent manner
(Fig. 5 A). Although the addition of IFN-g failed to restore
the ability of these cells to produce IFN-g upon secondary
Figure 1. IL-12 and IFN-g have in-
dependent as well as complementary
effects on the maintenance of IL-
12Rb2 subunit expression. C57BL/6
wild-type, IFN-g2/2, and IL-122/2
were immunized with OVA; 10 d
later, LN cells were removed and cul-
tured for 3 d. (A) C57BL/6 wild-type
LN cells were stimulated in the pres-
ence of OVA with or without anti–IL-12 (10 mg/ml) or anti–IFN-g (10 mg/ml). (B) IFN-g2/2 LN cells were stimulated in the presence of OVA with
or without anti–IL-12 (10 mg/ml) or IL-12 (20 ng/ml). (C) IL-122/2 LN cells were stimulated in the presence of OVA with or without IFN-g (30 ng/
ml). Results shown are representative of four experiments each using LN cells pooled from five or more mice.
Figure 2. B10.S MBP-reactive, but not NP-reactive, T cell lines fail to
induce IL-12p40 production by peritoneal exudate macrophages. Short-
term T cell lines (106/ml) from B10.S (A) or SJL mice (B) were restimu-
lated with syngeneic peritoneal exudate macrophages (5 3 105/ml) with
or without antigen and IL-12p40 production was measured at 48 h.
Background levels of IL-12p40 were subtracted. Results shown are repre-
sentative of two experiments.
Figure 3. B10.S MBP-reac-
tive, but not NP-reactive, LN
cells fail to upregulate CD40L
upon activation. B10.S mice
were immunized with a combi-
nation of MBP and NP. On day
12, draining LN cells were re-
moved and cultured with anti-
gen for 3 d. Total RNA was ex-
tracted, and competitive PCR
was performed for CD40L and
b2 microglobulin. Data expres-
sed as the percentage change of
stimulated levels of CD40L/b2 microglobulin compared with back-
ground levels. Results are representative of three experiments each using
LN cells pooled from five or more mice.973 Chang et al.
stimulation (28), modest induction of IL-12Rb2 subunit
expression was seen (data not shown). The addition of
neutralizing antibodies to IL–12 or IFN-g to cultures of
NP-reactive B10.S LN cells (Fig. 5 B) or MBP-reactive
SJL LN cells (Fig. 5 C) inhibited the ability of these cells to
upregulate IL-12Rb2 subunit mRNA in response to anti-
genic stimulation. Thus, the complementary roles of endog-
enous IL-12 and IFN-g for optimal expression of IL-12Rb2
subunit seen in the response of C57BL/6 mice to OVA can
be extended to a second foreign antigen (NP) and an auto-
antigen (MBP).
Role of IL-10 in the Expression of IL-12Rb2 Subunit
mRNA. One possible explanation for the failure of B10.S
MBP-specific T cells to induce IL-12 production and to
upregulate IL-12Rb2 expression is that a major component
of the response to MBP in this strain is mediated by Th2
cells. However, we have previously failed to demonstrate
production of IL-4 or IL-10 by B10.S MBP-specific T cells
and treatment of B10.S mice with anti–IL-4 in vivo or
anti–IL-10 in vitro did not result in the induction of IFN-g
production (28). Furthermore, addition of anti–IL-4 in
vitro failed to restore the ability of these cells to express
IL-12Rb2 subunit (data not shown). However, our recent
demonstration that IL-10 production by antigen nonspe-
cific CD41 T cells regulates the proinflammatory effects of
IL-12 in vivo prompted us to more carefully examine the
role of IL-10 in the priming of B10.S mice to MBP in vivo
(20). B10.S mice were immunized with MBP/NP and si-
multaneously treated with neutralizing anti–IL-10 mAbs.
Neutralization of IL-10 in vivo and in vitro did not restore
the ability of MBP-reactive LN cells to express IL-12Rb2
subunit (Fig. 6 A) or to produce IFN-g (data not shown).
However, it should be emphasized that IL-10 had a potent
downregulatory effect on the expression the IL-12Rb2 in
vitro as the addition of exogenous IL-10 to cultures of
either B10.S NP-reactive or SJL MBP–primed LN cells
strongly inhibited upregulation of the expression of the
IL-12Rb2 subunit (Fig. 6, B and C).
The Failure of B10.S MBP-specific T Cells to Fully Differen-
tiate into Th1 Effectors Does Not Appear to Be Secondary to a
Decreased Functional Avidity of the TCR. One of the prob-
lems with the comparison of immune responses between
B10.S and SJL mice at the population level even with a
well-defined peptide antigen is that these two strains differ
by many background genes including the TCR gene com-
plex (32). Thus, as a result of distinct positive/negative se-
lection events in the thymus, the B10.S MBP-specific T
cell repertoire may be quantitatively smaller or exhibit an
overall lower affinity for the MBP87–106 peptide I-As com-
plex compared with similarly restricted SJL T cells. The av-
erage lower affinity of the B10.S MBP-specific TCRs
might result in impaired induction of CD40L and the cas-
cade of events leading to defective upregulation of the
IL-12Rb2 subunit. Targoni and Lehmann have shown that
immunization with low doses of peptide would generate
recall responses only from T cells with a high affinity TCR
for their MHC–peptide ligand (33). We immunized B10.S
and SJL mice with different amounts (50, 100, or 400 mg)
of MBP87–106 in CFA and measured T cell proliferation in
response to a broad range of peptide concentrations in vitro
Figure 4. The ability of LN cells to express IL-12Rb2 subunit mRNA
correlates with susceptibility to EAE. (A) B10.S and SJL were immunized
with MBP/NP. On day 12, draining LN cells were removed and cul-
tured with antigen or anti-CD3 for 3 d. Total RNA was extracted, and
Northern blot analysis was performed for IL-12Rb2 and b1 subunits, and
b-actin. Results shown are representative of five experiments each using
LN cells pooled from five or more mice. (B) T cells were purified from
LN cells from B10.S mice coimmunized with MBP/NP and subsequently
depleted of NK cells. These T cells were combined with T cell–depleted,
NK cell–depleted B10.S splenocytes and cultured with or without anti-
gen for 3 d. Dendritic cells and NK cells were undetectable by FACS®
analysis. Total RNA was extracted, and Northern blot analysis was per-
formed for IL-12Rb2 subunit and b-actin. Results are representative of
two experiments each using LN cells pooled from five or more mice.
Figure 5. Maintenance of IL-12Rb2
mRNA expression is dependent on the pres-
ence of IL-12 and IFN-g. (A) LN cells from
B10.S mice coimmunized with MBP/NP
were removed on day 12 after immunization
and cultured for 3 d in the presence or ab-
sence of MBP with or without IL-12 (2 or
0.2 ng/ml). Total RNA was extracted, and
Northern blot analysis was performed for
IL-12Rb2 subunit and b-actin. Results are
representative of three experiments each us-
ing LN cells pooled from five or more mice. (B) LN cells from B10.S mice coimmunized with MBP/NP were removed on day 12 after immunization and
cultured for 3 d in the presence of NP with or without anti–IL-12 (10 mg /ml) or anti–IFN-g (10 mg/ml). Total RNA was extracted, and Northern blot
analysis was performed for IL-12Rb2 subunit and b-actin. Results are representative of three experiments each using LN cells pooled from five or more
mice. (C) LN cells from SJL mice coimmunized with MBP/NP were removed on day 12 after immunization and cultured for 3 d in the presence of MBP
with or without anti–IL-12 (10 mg/ml) or anti–IFN-g (10 mg/ml). Total RNA was extracted, and Northern blot analysis was performed for IL-12Rb2
subunit and b-actin. Results are representative of three experiments each using LN cells pooled from five or more mice.974 IL-12 Receptor b2 Subunit and Autoimmunity
(Fig. 7). In several experiments of this type, no consistent
differences between SJL and B10.S mice were seen in the
magnitude of the proliferative responses or the shape of the
dose–response curves. Thus, it appears that the expansion
of MBP-reactive cells is similar in the two strains and that
no obvious difference exists in their functional avidity.
The Defect in IL-12Rb2 Subunit Expression by B10.S
MBP-specific T Cells Does Not Extend to Other Myelin Au-
toantigens. Several studies have suggested that B10.S mice
have a global defect in their responses to myelin autoanti-
gens as the incidence and/or severity of EAE in B10.S mice
immunized with PLP139–151 or with whole spinal cord ho-
mogenate was significantly less than that seen in similarly
immunized SJL mice. To examine whether a failure of IL-
12Rb2 subunit expression was also seen in response to
PLP, we immunized B10.S mice with a combination of
MBP and PLP in CFA. PLP- but not MBP-reactive LN
cells upregulated IL-12Rb2 subunit strongly in response to
antigenic stimulation (Fig. 8 A). Furthermore, PLP- but
not MBP-reactive LN cells produced large quantities of
IFN-g in response to antigenic stimulation in secondary
cultures (Fig. 8 B). To further address the question of
whether the encephalitogenicity of primed LN cells corre-
lated with their ability to express the IL-12Rb2 subunit,
we immunized B10.S mice with PLP139–151 or MBP87–106 in
CFA. 10 d later, we stimulated draining LN cells in vitro
with PLP or MBP for 4 d, then transferred the cells into
naive B10.S recipients. Transfer of PLP-reactive LN cells
resulted in a 30% incidence of EAE, whereas transfer of
MBP-reactive LN cells failed to induce EAE in any mice
(Fig. 8 C). Thus, the capacity of LN cells to transfer EAE was
found to correlate with their ability to express IL-12Rb2
subunit upon activation.
Discussion
Although CD41 Th1 lymphocytes have been implicated
as the effector cells in both animal models and human or-
gan-specific autoimmune diseases, the failure to identify a
single effector cytokine that is responsible for pathogenicity
has suggested that cytokine-targeted therapeutic approaches
to autoimmune disease should be directed against the pri-
mary cytokine responsible for the differentiation of Th1
cells, IL-12. Because the IL-12Rb2 subunit has been iden-
tified as the critical molecule involved in maintaining IL-12
responsiveness and in controlling Th1 lineage commit-
ment, we have focused our studies on critically examining
the requirements for induction of the IL-12Rb2 subunit
on CD41 T cells responding to autoantigens as well as con-
ventional foreign antigens. We have used cytokine-deficient
mice to establish a critical role for IL-12 itself, independent
of IFN-g, in the induction of IL-12Rb2 expression. Al-
though IFN-g was capable of upregulating IL-12Rb2 on T
cells derived from IL-122/2 mice, the level of expression was
always less than that seen on T cells from wild-type and
IFN-g2/2 mice. As IL-122/2 mice have been found to have
markedly deficient Th1 responses and to be resistant to
Th1-mediated autoimmune diseases (34), the significance
of this IL-12–independent, IFN-g–dependent pathway of
IL-12Rb2 upregulation remains to be determined. More
importantly, our studies with neutralizing antibodies in vitro
have clearly shown that both IL-12 and IFN-g play critical
roles in the upregulation of IL-12Rb2 on restimulation of
antigen-primed T cells in vitro from wild-type mice.
We have previously defined a critical role for IL-12 in
the cytokine cascade needed for activation of encephalito-
genic MBP-specific T cells from EAE-resistant B10.S mice
Figure 6. Treatment with
anti–IL-10 does not reverse the
defect in IL-12Rb2 expression
by B10.S MBP–reactive T cells.
(A) B10.S mice coimmunized
with MBP/NP were injected in-
traperitoneally with 1 mg of ei-
ther control IgG or anti–IL-10
on days 0, 3, and 6. Draining LN
cells were removed on day 12 af-
ter immunization and cultured
for 3 d with antigen with either
control IgG (10 mg/ml) or anti–
IL-10 (10 mg/ml). Total RNA
was extracted, and Northern
blot analysis was performed for
IL-12Rb2 subunit and b-actin.
Results are representative of two
experiments each using LN cells
pooled from two or more mice.
Addition of exogenous IL-10 in
vitro inhibits the expression of
IL-12Rb2 subunit mRNA. (B)
LN cells from B10.S mice coim-
munized with MBP/NP were
removed on day 12 after im-
munization and cultured for 3 d
in the presence of NP with or
without IL-10 (10 ng/ml). To-
tal RNA was extracted, and
Northern blot analysis was per-
formed for IL-12Rb2 subunit
and b-actin. Results are repre-
sentative of three experiments
each using LN cells pooled from
five or more mice. (B) LN cells from SJL mice coimmunized with MBP/
NP were removed on day 12 after immunization and cultured for 3 d in
the presence of MBP with or without IL-10 (10 ng/ml). Total RNA was
extracted, and Northern blot analysis was performed for IL-12Rb2 sub-
unit and b-actin. Results are representative of three experiments each us-
ing LN cells pooled from five or more mice.
Figure 7. B10.S mice were im-
munized with 50 (j), 100 (d), or
400  mg (r) of MBP87–106. SJL
mice were immunized with 50
(u), 100 (s), or 400 mg (e) of
MBP87–106. On day 10, LN cells
from each group were pooled
(n 5 2) and stimulated with con-
centrations of antigen ranging
from 100 to 1 mg. Wells were
pulsed with 1 mCi of [3H]thymi-
dine at 72 h and harvested 16 h
later. Background proliferation was
subtracted. Results shown are rep-
resentative of three experiments.975 Chang et al.
(28). Although we could induce Th1 differentiation with
pharmacological concentrations of IL-12, we did not deter-
mine whether the failure to normally generate MBP-speci-
fic Th1 cells in this strain involved deficient IL-12 produc-
tion or deficient IL-12Rb2 subunit expression. We have
now shown that the primary defect in the immune re-
sponse of the B10.S mouse to MBP is defective expression
of CD40L on the MBP-specific T cell population with
subsequent failure to generate IL-12 production from
APCs. This in turn leads to defective expression of suffi-
cient levels of IL-12Rb2 needed for Th1 differentiation.
The importance of CD40/CD40L interactions in the dif-
ferentiation of encephalitogenic effectors is supported by
the suppression of EAE induction by the administration of
blocking CD40L mAbs (35, 36). Our previous studies have
ruled out excessive production of IL-4 as the mechanism
responsible for defective MBP-specific Th1 differentiation
in the B10.S mouse (28). Neutralization of IL-10 in vivo
and in vitro also did not restore IL-12Rb2 expression by
the MBP-specific T cells. However, addition of exogenous
IL-10 to the in vitro culture exerted a powerful downregu-
latory influence on expression of IL-12Rb2 subunit by an-
tigen-specific T cells primed in vivo under Th1 conditions.
Presumably, IL-10 acted directly on the APCs in the cul-
tures to inhibit IL-12 production and thereby mimicked
the effects of the addition of anti–IL-12 (37). However, a
direct effect of IL-10 on the responding T cells remains a
possibility. In any case, it appears that once IL-12Rb2 sub-
unit expression is induced by IL-12 in vivo, IL-10 can act
to limit the level of functional IL-12Rb2 ultimately expressed.
Indeed, this step may be the most important therapeutic ef-
fect of IL-10 in the treatment of autoimmune disease.
The antigen-specific defect we have observed in the
CD40L/IL-12/IL-12Rb2 subunit pathway in MBP-speci-
fic B10.S T cells should be contrasted with the more global
defects of the B10.S strain in the response to myelin-
derived autoantigens reported by others (38, 39). It is likely
that this antigen-specific defect is superimposed over and
above a more global defect. First, although the addition of
exogenous IL-12 to cultures of B10.S MBP-reactive T cells
restored their capacity to transfer EAE, the resultant disease
was monophasic and less severe than the relapsing-remit-
ting course manifested by SJL recipients of syngeneic
MBP-primed T cells (28). Second, although we have dem-
onstrated that B10.S PLP-reactive T cells can induce dis-
ease upon adoptive transfer, it should be noted that disease
incidence and severity were much less than those observed
in SJL mice. Furthermore, production of IFN-g was only
observed during secondary but not primary stimulation in
vitro. The differences between our results and those of
Encinas et al., who reported complete resistance of B10.S
mice to PLP-induced EAE, may be secondary to the differ-
ent disease induction protocols used (active induction ver-
sus passive transfer) or differences in the mouse colonies
consequent to genetic drift (38). Thus, B10.S mice appear
to have inherited a set of traits that confer a certain degree
of protection against autoimmune phenomena in general,
distinct from the antigen-specific defect in the IL-12
pathway. This set of traits is presumably mediated by the
products of non–H-2 background genes and may also be
responsible for the monophasic (as opposed to relapsing-
remitting) course of EAE exhibited by B10.PL mice as well
as for the resistance of C57BL/6 mice to autoimmune or-
chitis. In this context, it is interesting to note that one of
the genetic loci found to be important in susceptibility to
EAE (eae7) colocalizes to the same region of chromosome
11 as Orch3, a susceptibility locus in autoimmune orchitis
(39). Hence, in the case of the B10.S response to MBP, we
believe that absolute resistance arises as a result of the anti-
gen-specific defect superimposed on a more global pattern
of resistance to the manifestations of autoimmune disease.
What then is the mechanism responsible for the genera-
tion of this antigen-specific defect in the capacity of a pop-
ulation of autoreactive T cells to differentiate into patho-
genic Th1 effector cells? The simplest explanation is that it
is secondary to the size of the T cell repertoire specific for
MBP. We believe that this is unlikely as the magnitude of
the proliferative responses and of IL-2/IL-3 production by
B10.S mice to MBP does not differ significantly from that
of SJL mice (28). However, this question will only be able
to be addressed quantitatively when specific peptide-MHC
binding T cells are measured in this model. It is also possi-
ble that the affinity of the interaction of the anti-MBP
TCRs from B10.S mice with the MBP peptide–I-As
Figure 8. The ability of PLP-reactive LN cells to
express IL-12Rb2 subunit mRNA correlates with
their capacity to transfer EAE. (A) B10.S mice were
immunized with a combination of MBP and PLP.
On day 12, draining LN cells were removed and
cultured with antigen for 3 d. Total RNA was ex-
tracted, and Northern blot analysis was performed
for IL-12Rb2 subunit and b-actin. Results are rep-
resentative of three experiments each using LN cells
pooled from five or more mice. (B) B10.S mice
were immunized with either MBP or PLP. On day
12, draining LN cells were removed and cultured
with antigen for 4 d. Cells were extensively washed
and restimulated with or without antigen for 48 h, and IFN-g production was assayed by ELISA. Results are representative of two experiments each us-
ing LN cells pooled from 10 or more mice. (C) B10.S mice were immunized with MBP/PLP. On day 10, draining LN cells were removed and cultured
with antigen for 4 d. The cells were then washed and injected (6 3 107 cells intraperitoneally per mouse) into naive recipients. Animals were monitored
daily for neurological signs. Results shown are representative of two experiments performed with at least eight mice in each group.976 IL-12 Receptor b2 Subunit and Autoimmunity
complex is too low to generate a sufficient signal to trigger
high enough levels of CD40L expression to trigger the
IL-12 production cascade. However, we detected no differ-
ences between the proliferative capacities of B10.S and SJL
MBP87–106  reactive populations after immunization with
limited doses of peptide, suggesting that there are no major
differences in TCR avidity. It is also unlikely that the failure
of the B10.S T cells to differentiate is secondary to the de-
livery of a suboptimal costimulatory signal which potentially
could influence CD40L expression, as the addition of anti-
CD28 to B10.S cells in vitro failed to generate antigen-
specific IFN-g production (our unpublished observations).
We propose that the defect in the B10.S MBP-specific
population is generated during the process of negative se-
lection during thymic differentiation. Two recent studies in
shiverer mice, which have a mutation in the MBP gene,
have suggested that those autoantigen-specific T cells that
normally escape negative selection in the thymus to enter
the peripheral T cell pool do so because of their low affin-
ity for the autoantigen (33, 40). Yet, MBP87–106–specific T
cells from B10.S mice appear to have emerged from the
negative selection process with an additional defect—a
blunted capacity to become pathogenic effectors even
when primed under conditions that readily generate such
effectors in susceptible strains of mice such as the SJL or
B10.PL. We have previously postulated that one mecha-
nism by which autoreactive T cells may escape deletion in
the thymus is secondary to complete downregulation of
their TCR signaling properties with a major defect in their
capacity to produce IL-2 (41). Such cells, which are char-
acterized by expression of the CD25 antigen, appear to
function as suppressor cells that prevent organ-specific au-
toimmunity after thymectomy early in life. The B10.S
MBP–specific cells appear to be the products of a different
fail-safe mechanism imposed on the autoreactive T cell
repertoire during negative selection—the inability to up-
regulate the CD40L antigen and the subsequent IL-12 cas-
cade. Thus, negative selection of autoreactive TCRs may
be a more complex process than simple killing of high af-
finity cells and allowing low affinity cells to pass through.
Intrathymically, some autoreactive T cells may recognize
their target autoantigen in a qualitatively different way sim-
ilar to the manner in which mature T cells recognize al-
tered peptide ligands. However, at this stage of their devel-
opment, this altered recognition of self may result in a
variety of permanent defects in the TCR signal transduction
cascade ranging from anergy to the partial defect we have
described in the MBP-reactive population of the B10.S
mouse. This model does not exclude the possibility that the
expression of autoantigens, such as MBP, in the periphery
may also be required for the maintenance of the nonpatho-
genic state of the autoreactive T cells. We suspect that other
interesting phenotypes involving the inability of autoreactive
cells to fully differentiate will be uncovered in the future.
What are the implications of these results for the patho-
genesis of organ-specific autoimmune disease in experi-
mental animals and in man? B10.S MBP-reactive T cells
defy simple categorization into the Th1/Th2 paradigm. They
differ from Th1 cells by failing to upregulate IL-12Rb2 to an
appreciable degree upon activation. However, they also
differ from Th2 cells by retaining the capacity to express
IL-12Rb2 when triggered under conducive environmental
conditions. B10.S MBP-reactive cells fall within a distinct
subset of Th cells, which we refer to as Tpre-A cells, signify-
ing a latent ability to develop into autoimmune effectors.
We have found that IL-12–inducing microbial components
or high doses of recombinant IL-12 can serve as triggers for
the conversion of Tpre-A cells (27, 28). This may explain, in
part, why infectious diseases are so effective in precipitating
the onset and exacerbation of autoimmune diseases, includ-
ing multiple sclerosis (MS). Tpre-A cells may comprise a sig-
nificant number of autoreactive T cells in the periphery of
healthy individuals. Hence, defining those conditions that
favor as well as suppress their conversion into mature au-
toimmune effectors could have important clinical implica-
tions regarding the prevention of autoimmune disease and its
recurrences. Similar numbers of myelin protein–reactive T
cells have been detected in the peripheral blood of MS pa-
tients and healthy HLA-matched controls (42–46). The anti-
gen-specific inducibility of the IL-12Rb2 subunit and/or
CD40L may potentially serve as more reliable distinguishing
characteristics of pathogenic myelin protein–reactive T cells
from MS patients. If a recurrent pattern is established,
IL-12Rb2 subunit or CD40L expression may eventually
serve as a marker to detect subclinical disease and measure
active disease in MS. Furthermore, the development of im-
munotherapies that target subsets of T cells expressing high
levels of the IL-12Rb2 subunit may be warranted.
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